Overview

Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)

Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the effect of anakinra, 100 mg once daily (QD), on the development of an anti-tetanus antibody response in subjects with RA after vaccination with a tetanus and diphtheria toxoids injection. In addition, this study will evaluate the general safety profile of therapy with anakinra, 100 mg QD, in subjects with RA after vaccination with a tetanus and diphtheria toxoids injection.
Phase:
Phase 4
Details
Lead Sponsor:
Amgen
Treatments:
Interleukin 1 Receptor Antagonist Protein